Detalhe da pesquisa
1.
Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study.
Haematologica
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38426292
2.
Update and European consensus on a patient-centered core outcome set for multiple myeloma in clinical practice and research.
Haematologica
; 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38299690
3.
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study.
Eur J Haematol
; 112(3): 402-411, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37968873
4.
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.
Am J Hematol
; 99(5): 1008-1011, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38425185
5.
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Lancet Oncol
; 24(6): e255-e269, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37269857
6.
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group.
Lancet Oncol
; 24(7): e293-e311, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414019
7.
Prevention of infections including vaccination strategies in multiple myeloma.
Am J Hematol
; 98 Suppl 2: S46-S62, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36251367
8.
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
Lancet Oncol
; 22(3): e105-e118, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33662288
9.
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR.
Blood
; 133(2): 147-155, 2019 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30478094
10.
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
Haematologica
; 106(11): 2799-2812, 2021 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34261295
11.
The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour gene.
Br J Haematol
; 190(6): 877-890, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32232850
12.
Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment.
Oncologist
; 25(9): e1406-e1413, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32335971
13.
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.
Blood
; 131(3): 301-310, 2018 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29150421
14.
Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data.
Qual Life Res
; 29(1): 69-79, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31552577
15.
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.
Lancet Oncol
; 20(6): e302-e312, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31162104
16.
Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma.
Br J Cancer
; 121(9): 751-757, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31558804
17.
How I manage the toxicities of myeloma drugs.
Blood
; 129(17): 2359-2367, 2017 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28275090
18.
Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.
Haematologica
; 104(12): 2358-2360, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31439675
19.
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Ann Hematol
; 98(9): 2139-2150, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31240472
20.
Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.
Future Oncol
; 15(8): 897-907, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30827127